期刊
EXPERIMENTAL PHYSIOLOGY
卷 -, 期 -, 页码 -出版社
WILEY
DOI: 10.1113/EP090436
关键词
Duchenne muscular dystrophy; Friedreich's ataxia; gene therapy; Pompe disease; skeletal and cardiac muscle disease; therapeutics
类别
Skeletal myopathies and ataxias with secondary cardiac involvement are complex and progressive diseases. As life expectancy increases, it is necessary to develop targeted therapies to address the evolving cardiac pathologies.
Skeletal myopathies and ataxias with secondary cardiac involvement are complex, progressive and debilitating conditions. As life expectancy increases across these conditions, cardiac involvement often becomes more prominent. This highlights the need for targeted therapies that address these evolving cardiac pathologies. Musculopathies by and large lack cures that directly target the genetic basis of the diseases; however, as our understanding of the genetic causes of these conditions has evolved, it has become tractable to develop targeted therapies using biologics, to design precision approaches to target the primary genetic causes of these varied diseases. Using the examples of Duchenne muscular dystrophy, Friedreich ataxia and Pompe disease, we discuss how the genetic causes of such diseases derail diverse homeostatic, energetic and signalling pathways, which span multiple cellular systems in varied tissues across the body. We outline existing therapeutics and treatments in the context of emerging novel genetic approaches. We discuss the hurdles that the field must overcome to deliver targeted therapies across the many tissue types affected in primary myopathies
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据